Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trialHuabin Hu, Yanhong Deng, Liang Kang et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 304
Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled TrialQiyuan Qin, Jianping Wang, Tenghui Ma et al.|Diseases of the Colon & Rectum|2016Cited by 165
Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with <i>RAS</i>/<i>BRAF</i> Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II TrialHuabin Hu, Yanhong Deng, Kun Wang et al.|The Oncologist|2020Cited by 50
mFOLFOXIRI with or without bevacizumab for conversion therapy of RAS/BRAF/PIK3CA mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trialCailu Shen, Yanhong Deng, Huabin Hu et al.|Annals of Translational Medicine|2022Cited by 9
Utility of circulating tumor DNA in genomic profiling of colorectal cancer with peritoneal metastasis.Tenghui Ma, Hui Wang, Mingming Yuan et al.|Journal of Clinical Oncology|2020Cited by 1